Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 5/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712004 | 0.89 | KDM1A (0.40) | CNR1CNR2KDM1AMAOAMAOB | |
| SCHEMBL5519016 | 0.78 | GBA1 (0.34) | — | |
| Bromide SCHEMBL28426746 | 0.77 | GBA1 (0.33) | — | |
| SCHEMBL10037070 | 0.75 | EPHX2 (0.37) | KDM1AMAOAMAOB | |
| SCHEMBL13331319 | 0.74 | GBA1 (0.30) | — | |
| SCHEMBL24310936 | 0.73 | EPHX2 (0.40) | KDM1AMAOAMAOB | |
| SCHEMBL22906294 | 0.73 | EPHX2 (0.40) | KDM1AMAOAMAOB | |
| SCHEMBL22893117 | 0.73 | EPHX2 (0.40) | KDM1AMAOAMAOB | |
| SCHEMBL22893113 | 0.73 | EPHX2 (0.40) | KDM1AMAOAMAOB | |
| Iodide SCHEMBL2647139 | 0.73 | EPHX2 (0.36) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | CNR1 1266/4885CNR2 260/4885KDM1A 1950/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | CNR1 2388/4885CNR2 900/4885KDM1A 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.